期刊文献+

晚期非小细胞肺癌使用培美曲塞化疗 被引量:3

下载PDF
导出
摘要 目的对晚期非小细胞肺癌患者采用培美曲塞进行化疗的临床效果进行分析探讨。方法随机抽取在2009年1月至2012年1月间我院收治的1线化疗失败或者是无法耐受的晚期非小细胞肺癌患者病例76例,将其分成对照组和观察组,分别采用多西紫杉醇和培美曲塞进行治疗,并对其临床疗效进行对比分析。结果经统计发现,观察组与对照组患者的有效率分别为13.16%和10.53%;疾病控制率分别为55.26%和55.26%;中位生存时间分别为8.3个月和8.2个月。显然以上观察指标间差异不存在统计学意义(P>0.05)。观察组患者出现中性粒细胞减少的概率显著较对照组低,且差异具有统计学意义(P<0.05)。结论采用培美曲塞对晚期非小细胞肺癌患者进行化疗的临床疗效相对显著,且具有较高的安全性,值得对其进行推广使用。
作者 季名扬
出处 《中国医药指南》 2012年第34期518-519,共2页 Guide of China Medicine
  • 相关文献

参考文献5

二级参考文献49

  • 1李树婷,马飞,孙燕.抗肿瘤代谢新药——培美曲塞[J].癌症进展,2005,3(5):471-476. 被引量:73
  • 2陈鹏,熊海林,李丽庆,张爱莲,李凯.GP与TP方案治疗晚期非小细胞肺癌随机对照研究[J].天津医科大学学报,2006,12(2):246-249. 被引量:4
  • 3王莉.培美曲塞治疗非小细胞肺癌[J].癌症进展,2006,4(5):440-443. 被引量:10
  • 4Fisherman JS,McCabe M, Noone M,et al. Phsae I study of Taxol doxorubicin, plus granulocyte-colony stimulating factor in patients with metastatic breast cancer[J]. J Natl Cancer Inst Monogr, 1993 (15) : 189-194.
  • 5Pirker R, Krajnik G, Zochbauer S, et al. Paclitaxe/cisplatin in advanced non-small-cell lung cancer(NCLC) [J]. Ann Oncoh 1995, 6 (8) :833-835.
  • 6Stierle A, Strobel G, Stierle D,et al. The search for a taxol-producing microorganism among the endophytic fungi of the Pacific yew, Taxus brevifolia[J].Nat Prod, 1995, 58(9) : 1315-1324.
  • 7Zhang JA, Anyarambhatla G, Ma L, et al. Development and characterization of a novel Cremophor EL free liposome-based paclitaxel (LEP-ETU) fromulation[J]. Eur J Pharm Biopharm, 2005, 59(1).. 177-187.
  • 8Gelderblom H, Verweij J, Nooter K, et al. Cremophor EL: the draw backs and advantages of vehicle selection for drug formulation[J]. Eur J Cancer, 2001, 37(13) : 1590-1598.
  • 9Strubinger RM, Sharma A, Murray M,etal. Novel Taxol formulations: Taxol-containing liposome[J]. J Natl Cancer Inst Monogr, 1993(15) :69-78.
  • 10Yoichiro O. Chemoradiotherapy for lung cancer[J]. Expert Opin on Pharmacother, 2005, 6(16) :2793-2804.

共引文献77

同被引文献32

  • 1曹江.培美曲塞二钠治疗晚期非小细胞肺癌的研究[J].求医问药(下半月),2013(9):272-273. 被引量:1
  • 2王同杉,游思洪,葛红梅,陈子庆,丁小健,刘平.凋亡抑制蛋白livin在人胃癌中的表达以及和survivin表达的关系[J].南京医科大学学报(自然科学版),2006,26(1):39-43. 被引量:49
  • 3刘静,张柳清,胡群,林汉华,刘爱国,陶红芳,侯燕,张小玲,宋艳清,胡迎.Survivin、细胞周期素依赖激酶4、细胞增殖相关抗原在急性白血病患儿中表达的意义[J].实用儿科临床杂志,2006,21(9):545-546. 被引量:4
  • 4Parkin DM. Global cancer statistics in the year 2000[J]. Lancet Oncoi,2001,2(9) :533- 543.
  • 5Wang T, Nelson RA, Bogardus A, et al. Five year lung cancer survival:which advanced stage nonsmall cell lung cancer patients attain long-term survival? [J]. Cancer, 2010,116 (6) : 1518-1525.
  • 6Efinchez de Cos Essuln J, Disdier Vicente C, Corral Peflafiel J, et al. Overall long-term survival in lung cancer analyzed in 610 unselected patients[J]. Arch Bronconeumol, 2004,40 (6) : 268- 274.
  • 7Shepherd FA, Dancey J, Ramlau R, et al. Prospective ran- domized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy [J]. J Clin Oncol, 2000,18 (10) : 2095-2103.
  • 8Fossella FV,DeVore R,Kerr RN,et al. Randomized phase Ⅲ trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small-cell lung cancer previ ously treated with platinum-containing chemotherapy reg imens. The TAX 320 Non-Small Cell I.ung Cancer Study Group[J]. J Clin Oncol, 2000,18(12) : 2354-2362.
  • 9Hanna N, Shepherd FA, Fossella FV, et al. Randomized phase Ⅲ trial of pemetrexed versus docetaxel in patients with non-small cell lung cancer previously treated with chemotherapy[J]. J Clin Oncol,2004,22(9) : 1589-1597.
  • 10Vergnenegre A, Corre R, Berard H, et al. Cost-effective- ness of second Lin chemotherapy for nonsmall cell lung cancer an economic, randomized, prospective, multicenter phase Ⅲ trial comparing docetaxel and pemetrexed= the GFPC 05-06 studyFJ]. J Thorac Oncol,2011,6 (1) : 161- 168.

引证文献3

二级引证文献13

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部